Mankind Pharma Acquires Belgian Biotech Armed Cell Therapeutics
What happened
Mankind Pharma acquired a 70% stake in Armed Cell Therapeutics BV, a biotechnology company incorporated in Belgium. The acquisition, valued at 48 million euros, allows Mankind Pharma to enter the cell- and gene-therapy segment to treat cancer, including lymphomas and lung cancers. Armed Cell Therapeutics has a pipeline of next-generation CAR-T assets for non-Hodgkin lymphoma and small-cell lung cancer.
From vccircle.com
Why it matters
The acquisition is a strategic move for Mankind Pharma to build a global pipeline of breakthrough therapies. The deal involves Mankind's subsidiary, Mankind Netherlands, and utilizes a 50 million euro investment into the Netherlands subsidiary. Armed Cell Therapeutics maintains research operations in Pittsburgh.
From vccircle.com
Who's involved
- BelgiumCountry where Armed Cell Therapeutics BV is incorporated
- PittsburghLocation where Armed Cell Therapeutics conducts research operations
- NetherlandsCountry where Mankind Pharma's subsidiary, Mankind Netherlands, is based
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NetherlandsSpeculative
Mankind's investment might drive capital inflow into Mankind Netherlands.
Keep exploring
The entities involved
-
Netherlands
one of the four autonomous countries of the Kingdom of the Netherlands; with territories in the Caribbean
-
Belgium
country in western Europe
-
Pittsburgh
city and county seat in Allegheny County, Pennsylvania, United States